Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3149487 | 0.95 | CYP4A11 (0.50) | PTPN11CYP4A11LOXL2LCKCA2 | |
| SCHEMBL4940300 | 0.92 | KDM4E (0.55) | PTPN11CA2CA12CA7CA9 | |
| SCHEMBL17585028 | 0.88 | NPC1 (0.49) | PTPN11CYP4A11LOXL2LCKCA2 | |
| SCHEMBL12015399 | 0.88 | PTPN11 (0.55) | PTPN11CYP4A11LOXL2LCKCA2 | |
| SCHEMBL9939192 | 0.87 | EGFR (0.51) | CYP4A11LOXL2CA2CA12CA7 | |
| SCHEMBL29365729 | 0.85 | PTPN11 (0.68) | PTPN11LCKCA2CA12CA7 | |
| SCHEMBL69025 | 0.85 | PTPN11 (0.68) | PTPN11LCKCA2CA12CA7 | |
| SCHEMBL30917343 | 0.85 | PTPN11 (0.53) | PTPN11CYP4A11LOXL2LCKCA2 | |
| SCHEMBL16485169 | 0.85 | PTPN11 (0.53) | PTPN11CYP4A11LOXL2LCKCA2 | |
| SCHEMBL7440151 | 0.85 | PTPN11 (0.53) | PTPN11CYP4A11LOXL2LCKCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20220119401-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3851440-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | Medshine Discovery Inc. (CN) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020052649-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | 南京明德新药研发有限公司 | 2020-03-19 | — | — | WO | disclosed |
| EP-2906543-B1 | ACYLPIPERAZINES AS INHIBITORS OF TRANSGLUTAMINASE AND THEIR USE IN MEDICINE | UNIV ASTON (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9656978-B2 | Acylpiperazines as inhibitors of transglutaminase and their use in medicine | ASTON UNIVERSITY (GB) | 2017-05-23 | — | — | US | disclosed |
| EP-1615890-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1284267-B1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | SANKYO CO (JP) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004089903-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
| US-6653330-B2 | Such as 4'-chloro-4-(5-(3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4 -triazol-1-y)butyl)-1,3-dioxan-2-yl)-benzanilide; antifungal activity | SANKYO COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | SANKYO COMPANY, LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1284267-A1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | Sankyo Company, Limited (JP) | 2003-02-19 | — | — | EP | disclosed |
| US-4518609-A | ANTITUMOR, SKIN DISORDERS | SRI INTERNATIONAL (US) | 1985-05-21 | — | — | US | disclosed |
| US-4456618-A | ANTITUMOR AGENTS, TREATMENT OF SKIN DISORDERS | SRI INTERNATIONAL (US) | 1984-06-26 | — | — | US | disclosed |
| US-4130719-A | POLY(METHYLENEBENZOATES | STANDARD OIL COMPANY (INDIANA) (US) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119401-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | KDM1B, KDM1A, KDM7A | PTPN11 1243/4885CYP4A11 172/4885LOXL2 645/4885 |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | PTPN11 2150/4885CYP4A11 3001/4885LOXL2 3974/4885 |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | NAT1, ERG28, DPM1 | PTPN11 1306/4885CYP4A11 239/4885LOXL2 2752/4885 |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | KDM1B, KDM1A, KDM7A | PTPN11 1243/4885CYP4A11 172/4885LOXL2 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.